We are live on ! Find out more
SXTC icon

China SXT Pharmaceuticals
SXTC

5 hedge funds and large institutions have $79.9K invested in China SXT Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,409% more capital invested

Capital invested by funds: $3.19K → $79.9K (+$76.8K)

400% more funds holding

Funds holding: 1 → 5 (+4)

0.01% more ownership

Funds ownership: 0% → 0.01% (+0.01%)

Holders
5
Holders Change
+4
Holders Change %
+400%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$36.9K
2
Citadel Advisors
Citadel Advisors
Florida
+$18.4K
3
UBS Group
UBS Group
Switzerland
+$14.2K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$11.3K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
VF
1
Virtu Financial
New York
$34K +$36.9K +26 New
Citadel Advisors
2
Citadel Advisors
Florida
$17.4K +$18.4K +13 New
UBS Group
3
UBS Group
Switzerland
$13.7K +$14.2K +10 New
Bank of Montreal
4
Bank of Montreal
Ontario, Canada
$12.5K +$11.3K +8 New
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$2K – – –
Qube Research & Technologies (QRT)
6
Qube Research & Technologies (QRT)
United Kingdom
$327 – – –

SXTC Hedge Fund Activity: Q2 2024 in Review

5 of the 6,927 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q2 2024, worth a combined $79.9K — up 2,409% from $3.19K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new SXTC positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $36.9K.

  • 5 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q2 2024, up from 1 in Q1 2024.
  • Funds reported $79.9K of China SXT Pharmaceuticals stock for Q2 2024, up 2,409% quarter-over-quarter.
  • 4 funds opened new China SXT Pharmaceuticals positions in Q2 2024 and 0 closed out, a net change of +4 holders.
  • The largest China SXT Pharmaceuticals buyer in Q2 2024 was Virtu Financial, an estimated $36.9K added.

Based on aggregated 13F filings for Q2 2024.